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Gastric cancer (GC) is a highly aggres-
sive disease with a high incidence and an 
ominous prognosis, particularly in China, 
Brazil and some Mediterranean European 
countries [1]. Several environmental factors 
are involved in GC pathogenesis, in addi-
tion to genetic predisposition [1–3]. It is well 
known that lifestyle attitudes, such as high 
alcohol intake, tobacco consumption and 
spicy food, result in an increased suscepti-
bility for GC [2]. Screening program strate-
gies are not easy to establish in occidental 
countries, which has resulted in a late diag-
nosis at the advanced stage of the disease 
for the majority of GC cases. Over the past 
decade, approaches toward GC have been 
changing, particularly in the metastatic set-
ting. Platinum–fluoropyrimidine chemo-
therapy, however, remains the backbone 
for systemic treatment [1,4]. Furthermore, 
a set of patients with a good performance 
status may benefit from triplet regimens 
that include taxane [1,5]. More recently, 
molecular therapies have emerged with 
an additive effect, similar to that used 
with other tumor types (e.g., lung, mela-
noma) [6–9]. Trastuzumab (a monoclonal 
antibody against HER2), when added 
to standard platinum–fluoropyrimidine 
chemotherapy, showed an improved overall 
survival (OS) benefit in HER2-expressing 
(as identified by immunohistochemis-
try) GC patients [1,10]. Angiogenesis has 
been shown to play an active role in GC 
pathogenesis; hence, antiangiogenics have 
demonstrated benefits in the advanced set-
ting [3,6,11–12], with the urokinase plasmino-
gen activating system and VEGF recently 
being suggested to contribute synergisti-
cally to both tumor progression and aggres-
siveness [9,13]. In addition, HIF-1, a heter-
odimer comprising the oxygen-regulated 
subunit HIF-1α and HIF-1β, mediates the 
transcription of the gene for VEGF [13–15]. 
The overexpression of HIF-1α is associ-
ated with tumor neo-angiogenesis and 
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“...in the perioperative setting, a 
combination of apatinib with 
standard 
platinum–fluoropyrimidine 
chemotherapy may result in a 
clinical gain in terms of response.”
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sprouting and with tumor cell proliferation and 
invasion [14]. The role of VEGFA, B, C, D, E 
and its receptors (VEGFR1, VEGFR2 and 
VEGFR3) in several steps of tumor angiogen-
esis, lymphagiogenesis, cell proliferation and 
metastasis are well established in the litera-
ture [3]. Interestingly, the interaction between 
VEGFA and VEGFR2 effectively promoted the 
creation of novel tumor vessels via a stronger 
ligand–receptor binding, which resulted in cell 
downregulation that favored more rapid tumo-
rigenesis steps [2–3,9,12]. Although the interaction 
between VEGFA and VEGFR1 is effective, it is 
weaker in terms of ligand–receptor binding [8]. 
VEGFR3, in contrast, is more likely to be asso-
ciated with lymphangiogesis [3,8]. Thus, several 
angiogenesis-targeting drugs are being evaluated 
in the framework of systemic treatments [11,16–21].
In May 2016, an original article by Jin Li and 
coworkers [11] reported the results of a Phase III 
study using apatinib (an oral tyrosine kinase 
inhibitor of VEGFR2) in patients with refractory 
gastric or gastroesophageal junction (GEJ) can-
cer with two or more previous lines of treatment. 
The authors emphasized that although GC is cur-
rently the third cause of death from cancer world-
wide, there is still no standard treatment that has 
shown any satisfactory response or improved sur-
vival rates for those patients with refractory to 
chemotherapy gastric or GEJ cancer [11].
The study was supported by previous results 
from the promising use of antiangiogenic drugs 
in the treatment of GC [21]. In one study, beva-
cizumab (anti-VEGF), when used as a first-line 
therapy in combination with chemotherapy, 
was associated with increased response rates but 
not with OS [9,16,19]. Another study used ramu-
cirumab (anti-VEGFR2) as a second-line ther-
apy and showed increased OS, especially when 
combined with a taxane [19,21]. Finally, a Phase II 
randomized study from 2013 found increased OS 
rates for GC patients who were treated with apat-
inib after failure of chemotherapy, thus p roviding 
adequate support for a Phase III study [21].
Despite mentioning relevant studies, the 
authors failed to make any reference to the semi-
nal studies that pioneered targeted therapy for 
advanced GC, such as a study on anti-HER2 
therapy, in which trastuzumab combined with 
chemotherapy was associated with increased sur-
vival in advanced GC patients who expressed 
HER2 [1,10] or a study that discussed the major 
aspects of targeted therapy for advanced GC 
(especially anti-HER2 therapy) [1,10,20].
One study [11] was designed as a multicenter, 
placebo-controlled, Phase III trial with 273 
patients from 23 Chinese centers who were ran-
domized at 2:1 (176 receiving apatinib 850 mg 
orally, once a day and 71 receiving placebo). 
Randomization was used to increase the statis-
tical power of the study because of the small 
sample size. The primary end points were OS 
and progression-free survival. The secondary 
outcome parameters were response rate, quality 
of life and safety.
The patients in the two groups were matched, 
which facilitated comparisons. OS was sig-
nificantly longer (+1.8 months) in the treat-
ment group. Progression-free survival was also 
significantly longer with apatinib treatment 
(2.6 months) than with placebo treatment 
(1.8 months). The gain was slightly smaller than 
the gain in OS observed for the apatinib group 
in the Phase II study (2.3 months), despite the 
smaller sample size (n = 143). Thus, studies based 
on larger samples should be conducted to under-
stand these differences. In the overall analysis 
of safety, grade 3 and 4 toxicity, hand–foot syn-
drome, hypertension and h ematological toxicity 
were rarely observed.
The groups did not differ significantly in 
their quality of life scores at any time during the 
study period, which suggests that apatinib is a 
well-tolerated option.
The study of apatinib is relevant because no 
standard treatment has been established for 
patients with GC chemotherapy refractory dis-
ease. This is the first Phase III study [11] showing 
the efficacy of a well-tolerated oral antiangio-
genic drug in monotherapy for GC refractory 
to chemotherapy.
The authors [11] concluded that in addition 
to being less toxic than bevacizumab, apatinib 
is an attractive therapeutic option for patients 
with GC/GEJ cancer refractory to two lines 
of treatment and beyond. However, the lack of 
any effective options in patients with advanced 
GC refractory to more than two lines of chemo-
therapy makes apatinib an interesting alterna-
tive. Its effectiveness as a first-line therapy in the 
metastatic setting has yet to be proven, especially 
because trastuzumab with 5-fluorouracil and 
platinum-containing chemotherapy in HER2-
positive patients is considered successful. The 
median OS could even reach 17 months, accord-
ing to the ToGA trial [10]. Considering the lack 
of targeted drug options for HER2-negative GC 
patients in first-line therapy, apatinib combined 
“...trials in different disease 
settings and with a variety 
of these drug 
combinations are 
warranted to explore the 
optimal method and 
timing and to develop the 
best possible approach to 
provide better care for our 
patients.”
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with chemotherapy should be assessed both 
in this setting and as a maintenance therapy 
after satisfactory response to first-line chemo-
therapy. A well-designed clinical trial involv-
ing both patients with HER2-positive and 
HER2-negative disease is important to answer 
this question and clarify the remaining issues. 
Finally, the association of apatinib and standard 
chemotherapy should be evaluated in an adju-
vant or peri-operative framework to explore its 
benefits in terms of being a potential curative 
intended therapy. We also hypothesize that in 
the perioperative setting, a combination of apat-
inib with standard platinum–fluoropyrimidine 
chemotherapy may result in a clinical gain in 
terms of response. This notion is based on the 
fact that a bulky, potentially resectable disease 
carries a high tumoral burden, which could be 
more exposed and thus presents a better response 
to targeted therapy. Nevertheless, we should also 
be vigilant about the possible toxicity profile of 
this combination, predominantly the risks of 
bleeding and hypertension. In conclusion, trials 
in different disease settings and with a variety 
of these drug combinations are warranted to 
explore the optimal method and timing and to 
develop the best possible approach to provide 
better care for our patients.
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